Every other compound profile on this site follows the same format: mechanism, evidence, dosing context, safety, and a candidate framework describing who might reasonably consider it. Melanotan II gets a different treatment. Patients ask about it often enough — usually chasing a "sunless tan" or an off-label libido effect — that it needs a page, but the honest answer here is straightforward: the risk/benefit rationale is poor, the safety signal is real and specific to this compound's mechanism, and PeptideReport.ai does not recommend it. This page exists to explain why, not to help anyone use it.
Melanotan II activates melanocortin receptors broadly rather than selectively, which is the direct mechanistic explanation for both its tanning effect and its most concerning risks.
The evidence here is case-report level, not a large controlled study — and the Skin Cancer Foundation's own statement is careful to note that "case reports cannot establish direct causation." That caveat is worth taking seriously and does not weaken the caution: when the mechanism (melanocyte stimulation) provides a plausible causal pathway, the product is entirely unregulated, and the reported harm is melanoma, the appropriate response to case-report-level evidence is caution, not dismissal.
Confusion between Melanotan II and its structurally related, FDA-approved cousin afamelanotide (Scenesse®) is common and worth clearing up directly. Afamelanotide is derived from Melanotan I, a more selective MC1R agonist, and was FDA-approved in 2019 for a specific, serious photodermatosis — erythropoietic protoporphyria (EPP), a genetic condition causing severe pain on light exposure. It is administered as a controlled subcutaneous implant by a physician, in a monitored clinical setting, for a defined medical indication — the opposite, in nearly every relevant respect, of an unregulated, self-injected, non-selective compound purchased online for cosmetic tanning.
| Compound | Selectivity | Regulatory Status | Use Context |
|---|---|---|---|
| Afamelanotide (Scenesse®) | Selective MC1R agonist | FDA-Approved (2019) | Physician-administered implant for EPP, a diagnosed genetic photodermatosis |
| Melanotan II | Non-selective MC1R/MC3R/MC4R agonist | Not FDA-Approved | Self-injected, unregulated, cosmetic tanning / off-label libido use |
These are the questions PeptideReport.ai hears most often about Melanotan II. As with the rest of this profile, the answers stay direct rather than weighing tradeoffs — because for this compound, we don't think there's a meaningful tradeoff to weigh.
Melanotan II is not approved by the FDA for any use in the United States, and it is not a prescription medication. It is sold through unregulated online vendors, so its purity, actual dosage, and contents cannot be verified by any regulatory body. PeptideReport.ai treats the lack of FDA approval as one of the central reasons this compound does not carry an ordinary risk/benefit rationale.
Because Melanotan II non-selectively stimulates MC1R on melanocytes, it can accelerate changes in existing moles and pigmented lesions, and case reports have described new or changing pigmented lesions, including melanoma, following use. The Skin Cancer Foundation has issued a direct consumer warning citing these risks. Case reports alone cannot establish direct causation, but combined with this plausible mechanism, PeptideReport.ai treats the signal as one to take seriously rather than dismiss.
Afamelanotide is a more selective MC1R agonist that received FDA approval in 2019 for erythropoietic protoporphyria (EPP), a genetic photodermatosis, and is administered as a physician-placed subcutaneous implant in a monitored clinical setting. Melanotan II is a different, non-selective molecule that also activates MC3R and MC4R, is not FDA-approved for any indication, and is typically self-injected after being purchased from unregulated online sources for cosmetic tanning. Despite the similar name and shared receptor family, these are not interchangeable products.
No. This is one of the few compounds on this site presented as a cautionary profile rather than a candidate framework weighing pros and cons. The combination of a plausible melanoma mechanism, documented case reports, a direct Skin Cancer Foundation warning, and an entirely unregulated supply chain means the risk/benefit rationale is poor for essentially everyone, including people who simply want a cosmetic tan. Safer, evidence-based alternatives exist for that goal.
PeptideReport.ai does not publish a dosing, reconstitution, or administration protocol for Melanotan II, and this page will not provide one. Given the documented melanoma case reports, the Skin Cancer Foundation's consumer warning, and the fact that this compound is not FDA-approved or manufactured under any verified quality standard, there is no dose PeptideReport.ai considers safe enough to describe here.
The Skin Cancer Foundation's warning specifically cites systemic toxicity and muscle damage in addition to melanoma risk, and a separate case report documents injection-related changes in oral mucosal pigmentation, reflecting this compound's non-selective, systemic action on melanocytes rather than a skin-only effect. Sourcing is a risk on top of that: because Melanotan II is sold through unregulated online vendors, its purity, potency, and actual contents cannot be verified.